Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12

Molecular Pharmacology

Volumn 83, Issue 1, 2013, Pages 256-266

  Schmidt, Philipp ^a   Ritscher, Lars ^a   Dong, Elizabeth N ^b   Hermsdorf, Thomas ^a   Cöster, Maxi ^a   Wittkopf, Doreen ^a   Meiler, Jens ^b,c   Schöneberg, Torsten ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (METHYLTHIO)ADENOSINE DIPHOSPHATE; 2 (METHYLTHIO)ADENOSINE TRIPHOSPHATE; 2 IODOADENOSINE 5' (THIO)TRIPHOSPHATE; 2' (OR 3') O (TRINITROPHENYL)ADENOSINE DIPHOSPHATE; 2' (OR 3') O (TRINITROPHENYL)ADENOSINE TRIPHOSPHATE; ADENOSINE 5' (AMIDO)DIPHOSPHATE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MAMMAL CELL; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DATABASES, FACTUAL; DRUG INVERSE AGONISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MUTATION; PURINERGIC P2Y RECEPTOR AGONISTS; PURINES; RECEPTORS, PURINERGIC P2Y12; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871603139     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.082198     Document Type: Article

References (53)

1. Alexander N, Woetzel N, and Meiler J (2011) Bcl:Cluster: a method for clustering biological molecules coupled with visualization in the Pymol Molecular Graphics System, in2011 IEEE 1st International Conference on Computational Advances in Bio and Medical Sciences (ICCABS); 2004 February 3-5; Orlando, FL. pp 13-18, Institute of Electrical and Electronics Engineers, Piscataway, NJ
2. Baker JG, Hill SJ, and Summers RJ (2011) Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32:227-234.
3. Bakker RA, Jongejan A, Sansuk K, Hacksell U, Timmerman H, Brann MR, Weiner DM, Pardo L, and Leurs R (2008) Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors. Mol Pharmacol 73:94-103.
4. Barnard EA and Simon J (2001) An elusive receptor is finally caught: P2Y(12′), an important drug target in platelets. Trends Pharmacol Sci 22:388-391.
5. Beigi R, Kobatake E, Aizawa M, and Dubyak GR (1999) Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol 276:C267-C278.
6. Berridge MJ (1983) Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem J 212:849-858.
7. Bodor ET, Waldo GL, Blaesius R, and Harden TK (2004) Delineation of ligand binding and receptor signaling activities of purified P2Y receptors reconstituted with heterotrimeric G proteins. Purinergic Signal 1:43-49.
8. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, and Harden TK (2003) Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol 64:1210-1216.
9. Boudreaux MK and Martin M (2011) P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. Vet Clin Pathol 40:202-206.
10. Cattaneo M (2005) The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 31:168-173.
11. Cattaneo M, Lecchi A, Lombardi R, Gachet C, and Zighetti ML (2000) Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 20:E101-E106.
12. Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, and Ruggeri ZM (2003) Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 100:1978-1983.
13. Chee MJ, Mörl K, Lindner D, Merten N, Zamponi GW, Light PE, Beck-Sickinger AG, and Colmers WF (2008) The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor. J Biol Chem 283:33337-33346.
14. Daly ME, Dawood BB, and Lester WA et al. (2009) Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 113:4110-4113.
15. Davis IW and Baker D (2009) RosettaLigand docking with full ligand and receptor flexibility. J Mol Biol 385:381-392.
16. Deflorian F and Jacobson KA (2011) Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. J Comput Aided Mol Des 25:329-338.
17. Ding Z, Kim S, Dorsam RT, Jin J, and Kunapuli SP (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101:3908-3914.
18. Ding Z, Kim S, and Kunapuli SP (2006) Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 69:338-345.
19. Filtz TM, Li Q, Boyer JL, Nicholas RA, and Harden TK (1994) Expression of a cloned P2Y purinergic receptor that couples to phospholipase C. Mol Pharmacol 46:8-14.
20. Fontana G, Ware J, and Cattaneo M (2009) Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis. Haematologica 94:581-584.
21. Gupta SK, Pillarisetti K, Thomas RA, and Aiyar N (2001) Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 78:29-34.
22. Hoffmann K, Sixel U, Di Pasquale F, and von Kügelgen I (2008) Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor. Biochem Pharmacol 76:1201-1213.
23. Hollopeter G, Jantzen HM, and Vincent D et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207.
24. Ignatovica V, Megnis K, Lapins M, Schioth HB, and Klovins J (2011) Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system. FEBS J 279:180-191.
25. Kostenis E, Waelbroeck M, and Milligan G (2005) Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol Sci 26:595-602.
26. Lalueza-Fox C, Römpler H, and Caramelli D et al. (2007) A melanocortin 1 receptor allele suggests varying pigmentation among Neanderthals. Science 318:1453-1455.
27. Lazarowski ER, Homolya L, Boucher RC, and Harden TK (1997) Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 272:24348-24354.
28. Leaver-Fay A, Tyka M, and Lewis SM et al. (2011) ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487:545-574.
29. Li B, Scarselli M, Knudsen CD, Kim SK, Jacobson KA, McMillin SM, and Wess J (2007) Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods 4:169-174.
30. Meiler J and Baker D (2006) ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility. Proteins 65:538-548.
31. Muñoz-Esparza C, Jover E, Hernández-Romero D, Saura D, Valdés M, Lip GY, and Marín F (2011) Interactions between clopidogrel and proton pump inhibitors: a review of evidence. Curr Med Chem 18:2386-2400.
32. Nawarskas JJ and Clark SM (2011) Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev 19:95-100.
33. Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, Erb L, Weisman GA, Boucher RC, and Turner JT (1994) Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci USA 91:3275-3279.
34. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B, and Kwak S (2004) Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. Biochem Biophys Res Commun 324:171-177.
35. Remijn JA, IJsseldijk MJ, Strunk AL, Abbes AP, Engel H, Dikkeschei B, Dompeling EC, de Groot PG, and Slingerland RJ (2007) Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 45 :187-189.
36. Ritscher L, Engemaier E, Stäubert C, Liebscher I, Schmidt P, Hermsdorf T, Römpler H, Schulz A, and Schöneberg T (2012) The ligand specificity of the G-protein-coupled receptor GPR34. Biochem J 443:841-850.
37. Salomon Y, Londos C, and Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
38. Savi P, Labouret C, Delesque N, Guette F, Lupker J, and Herbert JM (2001) P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379-383.
39. Savi P, Zachayus JL, and Delesque-Touchard N et al. (2006) The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 103:11069-11074.
40. Schröder R, Janssen N, and Schmidt J et al. (2010) Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943-949.
41. Schulz A and Schöneberg T (2003) The structural evolution of a P2Y-like G-protein-coupled receptor. J Biol Chem 278:35531-35541.
42. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
43. Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, Kurata Y, Tomiyama Y, and Kanakura Y (2005) Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 3:2315-2323.
44. Simon J, Filippov AK, Göransson S, Wong YH, Frelin C, Michel AD, Brown DA, and Barnard EA (2002) Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 277:31390-31400.
45. Springthorpe B, Bailey A, and Barton P et al. (2007) From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17:6013-6018.
46. Storey RF (2011) Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 105 (Suppl 1):S75-S81.
47. Thor D, Le Duc D, Strotmann R, and Schöneberg T (2009) Luciferase activity under direct ligand-dependent control of a muscarinic acetylcholine receptor. BMC Biotechnol 9:46.
48. Thor D, Schulz A, Hermsdorf T, and Schöneberg T (2008) Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. Biochem J 412:103-112.
49. Vasiljev KS, Uri A, and Laitinen JT (2003) 2-Alkylthio-substituted platelet P2Y12 receptor antagonists reveal pharmacological identity between the rat brain Gi-linked ADP receptors and P2Y12. Neuropharmacology 45:145-154.
50. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, and Baumgartner HR (1979) Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood 54:1296-1319.
51. Yarov-Yarovoy V, Schonbrun J, and Baker D (2006) Multipass membrane protein structure prediction using Rosetta. Proteins 62:1010-1025.
52. Zhang FL, Luo L, and Gustafson E et al. (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276:8608-8615.
53. Zhong X, Kriz R, Seehra J, and Kumar R (2004) N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression. FEBS Lett 562:111-117.